|
|
Vol. 17.08 – 15 May, 2026
|
|
|
|
|
|
|
|
|
In preclinical models, C19-9N overcame enzalutamide resistance in CRPC xenografts, suppressed bone metastatic progression, and exhibited superior efficacy to platinum/taxane therapies in neuroendocrine prostate cancer. [Molecular Cancer]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
The authors identified ecotropic viral integration site 1 (EVI1) as an androgen receptor (AR)-recruited coactivator of noncanonical signaling. In prostate cancer, MECOM was exclusively overexpressed in both CRPC and enzalutamide-resistant CRPC and interacted with AR in the nucleus. [Cancer Research]
|
|
|
|
|
|
Scientists generated recombinant adenoviral vaccines encoding PSMA and LGALS9 for antigen expression in vitro and in vivo. They evaluated therapeutic efficacy in murine subcutaneous, bone metastatic, and humanized prostate cancer models.
[Journal for Immunotherapy of Cancer]
|
|
|
|
|
|
Researchers presented a detailed analysis of paired single-cell data collected before and after irreversible electroporation (IRE). They provided a first-in-human atlas of peripheral immune remodeling after IRE in localized prostate cancer.
[Journal for Immunotherapy of Cancer]
|
|
|
|
|
|
Using single-cell RNA sequencing of transgenic adenocarcinoma of the mouse prostate mice across pathological stages, investigators found an early neuroendocrine-initiating cluster marked by elevated HOXD11, conserved in human neuroendocrine prostate cancer. [Cell Reports]
|
|
|
|
|
|
Scientists showed that DEAD-box helicase 3 X-linked (DDX3X) colocalizes with androgen receptor (AR) mRNA in androgen receptor-low/negative CRPC cells and selectively recognizes non-canonical RNA G-quadruplex motifs within the sequence of AR mRNA.
[Oncogene]
|
|
|
|
|
|
Researchers demonstrated that RPS15 significantly promotes proliferation and migration in prostate cancer through the establishment of ribosomal protein S15 (RPS15) knockdown cells and xenograft models. [Oncogene]
|
|
|
|
|
|
|
|
Results from randomized Phase II trials support the use of metastasis-directed therapy in patients with metachronous oligometastatic prostate cancer. In parallel, prostate-directed treatments such as radiotherapy and cytoreductive radical prostatectomy are under investigation.
[Nature Reviews Urology]
|
|
|
|
|
|
Whilst inhibitors of the RAF-MEK-ERK-RSK pathway have demonstrated clinical utility in other cancers this has not been realized in prostate cancer. The reasons for this include a lack of predictive biomarkers for, and the unique landscape of pathway activation.
[British Journal of Cancer]
|
|
|
|
|
|
By integrating mechanistic, spatial, and clinical evidence, the authors propose a stage-aware framework for the gut–urinary–prostatic axis and delineate when microbial and metabolite signalling meaningfully conditions prostate disease biology—and when it does not. [Oncogene]
|
|
|
|
|
|
|
|
Drs. Pallabi Mustafi and Ruben Raychaudhuri received Young Investigator Awards from the Prostate Cancer Foundation for their work investigating epigenetic features of aggressive prostate cancer that could lead to more personalized care and better results from existing therapies. [Fred Hutch Cancer Center]
|
|
|
|
|
|
Does prostate-cancer screening with the common ‘PSA’ blood test save lives? The Cochrane has previously addressed that question twice, and twice the answer was ‘no’. Data from nearly 800,000 people has prompted a U-turn. [Nature]
|
|
|
|
|
|
|
|
June 22-23, 2026 New York City, New York, United States
|
|
|
|
|
|
|
|
|
|
|
Case Western Reserve University – Cleveland, Ohio, United States
|
|
|
|
|
|
|
Fred Hutchinson Cancer Center – Seattle, Washington, United States
|
|
|
|
|
|
|
The University of Texas MD Anderson Cancer Center – Houston, Texas, United States
|
|
|
|
|
|
|
Heidelberg University – Heidelberg, Germany
|
|
|
|
|
|
|
The University of Hong Kong – Hong Kong
|
|
|
|
|
|